INGELHEIM, Germany & BALTIMORE, Md.--(BUSINESS WIRE)--Boehringer Ingelheim and the Lieber Institute for Brain Development (LIBD) today announced a joint research and licensing collaboration focused on ...
Hosted on MSN
Common Medications for Parkinson’s Disease
Parkinson’s disease is a condition that damages dopamine-producing brain cells, leading to tremors, stiffness, and difficulty with balance and coordination. Medications for Parkinson’s disease aim to ...
Catechol-O-methyltransferase (COMT) inhibitors have long been recognised for their clinical utility in managing neurological disorders, most notably Parkinson’s disease. By impeding the enzymatic ...
Amneal Pharmaceuticals (AMRX) announced new positive interim results from its ongoing Phase 4 ELEVATE-PD study, presented at the Parkinson’s Study ...
SAN DIEGO, July 10, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for ...
A randomized clinical trial examined patient quality of life in Parkinson disease (PD) when adding different adjuvant therapies to levodopa to help control dyskinesia and a flaring of symptoms during ...
Dopamine agonists and dopamine reuptake inhibitors (DRIs) appear to have equal efficacy for Parkinson's disease (PD) and motor fluctuations uncontrolled by levodopa. However, some DRIs are more ...
A once-daily add-on therapy for Parkinson's disease (PD) used in Europe for years has now gained clearance in the U.S. with FDA approval of Ongentys (opicapone). The drug, an improvement upon generics ...
Diagnosing patients via telehealth calls can be challenging, but especially when it comes to movement disorders. For Neurocrine Biosciences, that discovery was a pandemic-era double whammy. Two of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results